CJC-1295 + Ipamorelin: why they are often combined

Two different receptors, two different entry points into the GH axis — and a combined effect that is greater than the sum of either alone.

TL;DR

• CJC-1295 is a GHRH analog that binds the GHRH receptor on pituitary somatotrophs, while ipamorelin is a ghrelin/GHS-R agonist that binds a completely separate receptor — the ghrelin receptor (GHS-R1a).
• Administered together, they stimulate GH release through complementary pathways, producing a synergistic GH pulse that is larger than either compound alone.
• Ipamorelin is notable for its selectivity: unlike earlier GH secretagogues (GHRP-2, GHRP-6), it does not significantly raise cortisol or prolactin at therapeutic doses — a meaningful distinction documented in published pharmacology studies.

What it is

CJC-1295 (without DAC) is a modified GHRH analog — a synthetic version of growth-hormone-releasing hormone engineered for improved stability over natural GHRH. It binds to GHRH receptors (GHRHR) on somatotroph cells in the anterior pituitary, triggering the cellular cascade that produces and releases GH.

Ipamorelin is a pentapeptide — five amino acids — developed as a selective growth hormone secretagogue. It binds the ghrelin receptor (GHS-R1a), which is a distinct receptor from GHRHR expressed on a partially overlapping population of pituitary cells. The ghrelin receptor pathway represents a second, parallel mechanism for stimulating GH release.

These are not two versions of the same mechanism. They are two different doors into the same room.

How it works

The GH secretagogue receptor (GHS-R1a) and the GHRH receptor (GHRHR) are distinct G-protein-coupled receptors that converge on GH secretion through separate intracellular signaling cascades. Research has established that their simultaneous activation produces a synergistic response — a GH pulse larger than what GHRH or a ghrelin agonist produces alone (Bowers CY, Journal of Pediatric Endocrinology & Metabolism, 2001).

The clinical significance of ipamorelin’s selectivity was established in a key pharmacological study by Raun and colleagues at Novo Nordisk, which directly compared ipamorelin’s GH-stimulating effects to GHRP-2 and GHRP-6. The study found that ipamorelin stimulated GH release at potencies comparable to the older GHRPs, but with significantly lower stimulation of cortisol and prolactin secretion — effects that limited the clinical appeal of earlier secretagogues (Raun et al., European Journal of Endocrinology, 1998).

This selectivity matters: cortisol elevation is catabolic and counterproductive to most of the goals people pursue through GH-axis protocols. A GH pulse that comes with a cortisol spike is a less favorable trade-off than one that does not.

Who asks about it

CJC-1295 + ipamorelin is one of the most frequently discussed peptide combinations in functional medicine and longevity contexts. People ask about it after seeing it mentioned as a first-line GH secretagogue combination in physician-authored content, and often want to understand the mechanism behind the pairing — not just that it is commonly used, but why.

What the research says

The Raun et al. 1998 study remains the foundational pharmacological reference for ipamorelin’s selectivity profile, conducted in rats and pigs with GH, cortisol, ACTH, and prolactin measurements. The authors described ipamorelin as “the first selective GH secretagogue” — a characterization that holds up in subsequent literature.

CJC-1295’s pharmacokinetics were established by Teichman et al. (2006) in a randomized, placebo-controlled study in healthy adults, demonstrating dose-dependent GH elevation and sustained IGF-1 increases following single administration, with a half-life of approximately 6–8 days for the DAC formulation and approximately 30 minutes for the non-DAC form (Teichman et al., JCEM, 2006).

The combination’s synergy has been examined in studies on GH secretagogue co-administration, with the complementary receptor mechanism explanation supported across multiple literature reviews on GH axis pharmacology (Sigalos JT, Pastuszak AW, Sexual Medicine Reviews, 2018).

What to know before considering it

CJC-1295 + ipamorelin requires a clinician evaluation and valid prescription. Baseline IGF-1 testing is standard before starting a GH-axis protocol, and follow-up labs at 3 months help assess response. The combination is generally well-tolerated in physician-supervised protocols; published literature notes water retention and injection-site reactions as the most commonly reported effects at initiation. Individual response varies, and protocol design — dose, timing, cycling structure — should be determined by your clinician based on your lab results and goals.

The Halftime POV

The CJC-1295 + ipamorelin combination is the peptide equivalent of a well-designed two-part protocol: two complementary mechanisms, one shared goal. Neither compound is redundant — they address different receptor populations and produce an effect through convergent pathways. The selectivity of ipamorelin specifically is what made this combination a staple of functional medicine practice: it adds a ghrelin-receptor pathway without the cortisol trade-off that made older GHRPs less attractive. If you are going to explore GH-axis peptides, understanding why this particular pairing exists is the right place to start.

Related reading:

Disclaimer

This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.

Get updates

Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.

Sources

• Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology, 1998.
• Teichman SL, et al. Prolonged stimulation of GH and IGF-I secretion by CJC-1295. Journal of Clinical Endocrinology & Metabolism, 2006.
• Bowers CY. GH-releasing peptides — structure and kinetics. Journal of Pediatric Endocrinology & Metabolism, 2001.
• Sigalos JT, Pastuszak AW. The safety and efficacy of growth hormone secretagogues. Sexual Medicine Reviews, 2018.